PMCB: financial statements from SEC — TradeAlmanac

PMCB

PharmaCyte Biotech, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Jan 31, 2026	Oct 31, 2025	Jul 31, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024
Revenue	0	0	0	0	0	0
Research and development	93,113	141,085	95,157	118,196	97,470	96,016
Selling, general and administrative	2m	1m	753,148	842,056	1m	1m
Operating expenses	2m	1m	848,305	960,252	1m	1m
Operating income	−2m	−1m	−848,305	−960,252	−1m	−1m
Net income	746,860	−7m	−8m	−3m	−1m	23m
Earnings per share	−0.17	−1.24	−1.23	−0.44	−0.39	1.90
Earnings per share, diluted	−0.17	−1.24	−1.23	−0.44	−0.39	1.90
Weighted average shares	9m	7m	7m	7m	8m	8m
Weighted average shares, diluted	9m	7m	7m	7m	8m	8m

Balance sheet

Metric	Jan 31, 2026	Oct 31, 2025	Jul 31, 2025	Apr 30, 2025	Jan 31, 2025	Oct 31, 2024	Jul 31, 2024	Apr 30, 2024
Cash and equivalents	20m	15m	13m	15m	16m	21m	33m	50m
Short-term investments	372,251	201,190

Cash flow

Metric	Jul 31, 2025	Jul 31, 2024
Operating cash flow	−2m	−373,297
Share-based compensation	60,492	222,677
Investing cash flow	0	−7m
Share buybacks	0	742,179
Financing cash flow	0	−10m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)